HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lunde, E. Articles by Bogen, B. Search for Related Content PubMed PubMed Citation Articles by Lunde, E. Articles by Bogen, B.

Efficient Delivery of T Cell Epitopes to APC by Use of MHC Class II-Specific Troybodies¹

Elin Lunde^2,3,*, Karoline H. Western^2,*, Ingunn B. Rasmussen^2,, Inger Sandlie and Bjarne Bogen^*

^* Institute of Immunology, University of Oslo, National Hospital, Oslo, Norway; and Department of Biology, Division of Molecular Cell Biology, University of Oslo, Oslo, Norway

A major objective in vaccine development is the design of reagents that give strong, specific T cell responses. We have constructed a series of rAb with specificity for MHC class II (I-E). Each has one of four different class II-restricted T cell epitopes genetically introduced into the first C domain of the H chain. These four epitopes are: 91–101 2³¹⁵, which is presented by I-E^d; 110–120 hemagglutinin (I-E^d); 323–339 OVA (I-A^d); and 46–61 hen egg lysozyme (I-A^k). We denote such APC-specific, epitope-containing Ab "Troybodies." When mixed with APC, all four class II-specific Troybodies were 1,000 times more efficient at inducing specific T cell activation in vitro compared with nontargeting peptide Ab. Furthermore, they were 1,000–10,000 times more efficient than synthetic peptide or native protein. Conventional intracellular processing of the Troybodies was required to load the epitopes onto MHC class II. Different types of professional APC, such as purified B cells, dendritic cells, and macrophages, were equally efficient at processing and presenting the Troybodies. In vivo, class II-specific Troybodies were at least 100 times more efficient at targeting APC and activating TCR-transgenic T cells than were the nontargeting peptide Ab. Furthermore, they were 100–100,000 times more efficient than synthetic peptide or native protein. The study shows that class II-specific Troybodies can deliver a variety of T cell epitopes to professional APC for efficient presentation, in vitro as well as in vivo. Thus, Troybodies may be useful as tools in vaccine development.

This article has been cited by other articles:

				N. Dickgreber, P. Stoitzner, Y. Bai, K. M. Price, K. J. Farrand, K. Manning, C. E. Angel, P. R. Dunbar, F. Ronchese, J. D. Fraser, et al. Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy J. Immunol., February 1, 2009; 182(3): 1260 - 1269. [Abstract] [Full Text] [PDF]

				M. Flobakk, I. B. Rasmussen, E. Lunde, T. Frigstad, G. Berntzen, T. E. Michaelsen, B. Bogen, and I. Sandlie Processing of an Antigenic Sequence from IgG Constant Domains for Presentation by MHC Class II J. Immunol., November 15, 2008; 181(10): 7062 - 7072. [Abstract] [Full Text] [PDF]

				G. Tunheim, K. W. Schjetne, I. B. Rasmussen, L. M. Sollid, I. Sandlie, and B. Bogen Recombinant antibodies for delivery of antigen: a single loop between {beta}-strands in the constant region can accommodate long, complex and tandem T cell epitopes Int. Immunol., March 1, 2008; 20(3): 295 - 306. [Abstract] [Full Text] [PDF]

				L.-Z. He, A. Crocker, J. Lee, J. Mendoza-Ramirez, X.-T. Wang, L. A. Vitale, T. O'Neill, C. Petromilli, H.-F. Zhang, J. Lopez, et al. Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity J. Immunol., May 15, 2007; 178(10): 6259 - 6267. [Abstract] [Full Text] [PDF]

				E. J. McKenzie, P. R. Taylor, R. J. Stillion, A. D. Lucas, J. Harris, S. Gordon, and L. Martinez-Pomares Mannose Receptor Expression and Function Define a New Population of Murine Dendritic Cells J. Immunol., April 15, 2007; 178(8): 4975 - 4983. [Abstract] [Full Text] [PDF]

				K. W. Schjetne, A. B. Fredriksen, and B. Bogen Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors J. Immunol., April 1, 2007; 178(7): 4169 - 4176. [Abstract] [Full Text] [PDF]

				R. W. Carter, C. Thompson, D. M. Reid, S. Y. C. Wong, and D. F. Tough Preferential Induction of CD4+ T Cell Responses through In Vivo Targeting of Antigen to Dendritic Cell-Associated C-Type Lectin-1 J. Immunol., August 15, 2006; 177(4): 2276 - 2284. [Abstract] [Full Text] [PDF]

				G. Tunheim, K. W. Schjetne, A. B. Fredriksen, I. Sandlie, and B. Bogen Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes J. Leukoc. Biol., March 1, 2005; 77(3): 303 - 310. [Abstract] [Full Text] [PDF]

				K. W. Schjetne, K. M. Thompson, N. Nilsen, T. H. Flo, B. Fleckenstein, J.-G. Iversen, T. Espevik, and B. Bogen Cutting Edge: Link Between Innate and Adaptive Immunity: Toll-Like Receptor 2 Internalizes Antigen for Presentation to CD4+ T Cells and Could Be an Efficient Vaccine Target J. Immunol., July 1, 2003; 171(1): 32 - 36. [Abstract] [Full Text] [PDF]

				K. W. Schjetne, K. M. Thompson, T. Aarvak, B. Fleckenstein, L. M. Sollid, and B. Bogen A mouse C{kappa}-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation Int. Immunol., December 1, 2002; 14(12): 1423 - 1430. [Abstract] [Full Text] [PDF]